Abeona Therapeutics Inc. - Common Stock (ABEO)

Competitors to Abeona Therapeutics Inc. - Common Stock (ABEO)

bluebird bio, Inc. 

bluebird bio specializes in gene therapies for severe genetic diseases and cancers, and competes directly with Abeona in areas like adrenoleukodystrophy and sickle cell disease. The company has established its market presence through successful clinical trials and regulatory approvals, leading to commercialized products that provide therapeutic options not yet available from Abeona. Their advanced clinical stage products and established relationships with healthcare providers provide them a competitive advantage.

CRISPR Therapeutics AG 

CRISPR Therapeutics uses CRISPR/Cas9 gene editing technology to develop transformative gene-based medicines. They compete with Abeona by targeting similar therapeutic areas, such as genetic disorders and hematologic conditions. With their advanced technology and significant funding, CRISPR Therapeutics is well-positioned in the market and has a pipeline of promising therapies, giving them a competitive edge over Abeona in terms of innovation and market reach.

Editas Medicine, Inc. 

Editas Medicine utilizes CRISPR technology to develop genetic medicines aimed at treating a variety of severe diseases, including inherited conditions and cancers. They compete with Abeona by focusing on similar therapeutic targets and utilizing cutting-edge gene editing techniques that can potentially provide more efficacious solutions. While Abeona has a promising pipeline, Editas has made notable progress in commercialization and strategic partnerships, indicating a stronger foothold in the market.

Rocket Pharmaceuticals, Inc. 

Rocket Pharmaceuticals is developing gene therapies for rare genetic diseases and cancers, competing with Abeona primarily through its advanced pipeline focused on inherited bone marrow failures and leukodystrophies. Rocket’s established clinical programs, coupled with strong backing from investors and partnerships, provide it with a strategic advantage over Abeona in terms of funding and a faster progression through clinical trials.

Sangamo Therapeutics, Inc. 

Sangamo Therapeutics focuses on genomic medicine, particularly in gene therapy and gene editing technologies. This company competes with Abeona by advancing innovative treatments for genetic diseases, including hemophilia and lysosomal storage disorders. Sangamo boasts a strong intellectual property portfolio and has established partnerships with large pharmaceutical companies, which provide them with funding and resources to advance their therapies more rapidly than some newer entrants like Abeona.